Literature DB >> 10588144

Clinical follow-up after cessation of chronic electrical neuromodulation in patients with severe coronary artery disease: a prospective randomized controlled study on putative involvement of sympathetic activity.

G A Jessurun1, M J DeJongste, R W Hautvast, R A Tio, J Brouwer, S van Lelieveld, H J Crijns.   

Abstract

The present study assessed the reoccurrence of myocardial ischemia after withholding electrical neurostimulation. After randomization, in the study or withdrawal group, spinal cord stimulation (SCS) was set active during the first 4 weeks, followed by 4 weeks of withholding stimulation. In the control group, SCS was switched off during 4 weeks before the end of the study. The control group had no crossover period. Measurements were done at baseline, then after 4 and 8 weeks. The first periods at 4 weeks of each sequence of both groups were compared. In addition, a comparison of clinical variables was performed between the study group 4 weeks after withholding stimulation and the control group 4 weeks following randomization. A total number of 24 patients with refractory angina and an implanted spinal cord stimulator were included in the study (n = 12) and control group. Angina pectoris complaints, nitroglycerin intake, ischemia, and heart rate variability using 48-hour ambulatory electrocardiographic monitoring were assessed. In addition, neurohormonal status and symptom-limited aerobic capacity were evaluated. There was no increase of anginal complaints or ischemia after withholding stimulation. Neurohormonal levels and aerobic capacity were not altered. We conclude that there is no adverse clinical rebound phenomenon after withholding neurostimulation in patients with refractory angina pectoris.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588144     DOI: 10.1111/j.1540-8159.1999.tb00346.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  7 in total

1.  The effect of electrical neurostimulation on collateral perfusion.

Authors:  J de Vries; R L Anthonio; M J L DeJongste; G A Jessurun; R A Tio; F Zijlstra
Journal:  Neth Heart J       Date:  2006-06       Impact factor: 2.380

2.  Thoracic spinal cord stimulation improves functional status and relieves symptoms in patients with refractory angina pectoris: the first placebo-controlled randomised study.

Authors:  Stephan Eddicks; Klaus Maier-Hauff; Michael Schenk; Andreas Müller; Gert Baumann; Heinz Theres
Journal:  Heart       Date:  2007-01-19       Impact factor: 5.994

3.  The effectiveness and cost-effectiveness of spinal cord stimulation for refractory angina (RASCAL study): study protocol for a pilot randomized controlled trial.

Authors:  Sam Eldabe; John Raphael; Simon Thomson; Andrea Manca; Mark de Belder; Rajesh Aggarwal; Matthew Banks; Morag Brookes; Susan Merotra; Rashidat Adeniba; Ed Davies; Rod S Taylor
Journal:  Trials       Date:  2013-02-22       Impact factor: 2.279

Review 4.  Calming the Nervous Heart: Autonomic Therapies in Heart Failure.

Authors:  Peter Hanna; Kalyanam Shivkumar; Jeffrey L Ardell
Journal:  Card Fail Rev       Date:  2018-08

Review 5.  Spinal Cord Stimulation for Refractory Angina Pectoris: A Systematic Review and Meta-analysis.

Authors:  Xiaoxiao Pan; Hongguang Bao; Yanna Si; Chenjie Xu; Hao Chen; Xianzhong Gao; Xinyi Xie; Yajie Xu; Fan Sun; Lingqing Zeng
Journal:  Clin J Pain       Date:  2017-06       Impact factor: 3.442

6.  Spinal cord stimulation in the treatment of refractory angina: systematic review and meta-analysis of randomised controlled trials.

Authors:  Rod S Taylor; Jessica De Vries; Eric Buchser; Mike J L Dejongste
Journal:  BMC Cardiovasc Disord       Date:  2009-03-25       Impact factor: 2.298

7.  The effect of electrical neurostimulation on collateral perfusion during acute coronary occlusion.

Authors:  Jessica de Vries; Rutger L Anthonio; Mike J L Dejongste; Gillian A Jessurun; Eng-Shiong Tan; Bart J G L de Smet; Ad F M van den Heuvel; Michiel J Staal; Felix Zijlstra
Journal:  BMC Cardiovasc Disord       Date:  2007-06-27       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.